Reportlinker Adds Merck KGaA: PharmaVitae Profile

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Merck KGaA: PharmaVitae Profile

http://www.reportlinker.com/p0186215/Merck-KGaA-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Merck KGaA's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Merck KGaA over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector

See how Erbitux and six new launches will drive the company's sales growth

Assess the effects of Millipore on the company's non-prescription pharmaceutical sales

To order this report:

: Merck KGaA: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.